Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...
US stocks extended losses on Wednesday as weakness in tech megacaps outweighed solid economic data and mixed results from ...
Seven S&P 500 high-yield 'safer' dividend stocks—like Ford, AT&T, and VICI—offer strong payouts supported by free cash flow ...
Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.
Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...
Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...
Zacks Investment Research on MSN
Pfizer (PFE) ascends while market falls: Some facts to note
In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.09%, and the ...
Citigroup (NYSE:C) used its fourth-quarter 2025 earnings call to highlight a “strong quarter” and what CEO Jane Fraser ...
A weeklong rotation that has seen investors bail from richly priced technology names in favor of more economically sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback